Your browser doesn't support javascript.
loading
HDL Mimetic Peptides.
Chen, Jie; Liu, Jiewen; Yu, Baoqi.
Afiliación
  • Chen J; The Institute of Cardiovascular Sciences and Institute of Systems Biomedicine, School of Basic Medical Sciences, Key Laboratory of Molecular Cardiovascular Science of Ministry of Education, NHC Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Beijing Key Laboratory of Card
  • Liu J; McGill University, Montreal, QC, Canada.
  • Yu B; Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Capital Medical University, Beijing, China. baoqiyu@ccmu.edu.cn.
Adv Exp Med Biol ; 1377: 141-151, 2022.
Article en En | MEDLINE | ID: mdl-35575927
ABSTRACT
Since therapeutic strategies designed to raise HDL failed to exert the expected effective cardiovascular disease (CVD) outcomes in clinical trials, how to improve HDL function rather than its plasma level has become a new focus of scientists' attention. Numerous HDL mimetic peptides have been designed and investigated in various animal models in recent years. Although the underlying mechanisms are not fully understood, the peptides' antiatherogenic effects, such as acceleration of RCT and improvement of natural HDL function without necessarily raising its level, showed a promising therapeutic role in the prevention of atherosclerosis and other diseases. This chapter reviews recent studies on the roles and potentials of HDL mimetic peptides in atherosclerosis-related CVD.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Enfermedades Cardiovasculares / Aterosclerosis Límite: Animals Idioma: En Revista: Adv Exp Med Biol Año: 2022 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Enfermedades Cardiovasculares / Aterosclerosis Límite: Animals Idioma: En Revista: Adv Exp Med Biol Año: 2022 Tipo del documento: Article